Research programme: antibacterials - Roche

Drug Profile

Research programme: antibacterials - Roche

Alternative Names: 3,5-Diamino-piperidinyl triazines (DAPT) compounds - Roche; Bacteria ribosomal translation inhibitors - Roche; Bacterial translation inhibitors - Roche; DAPT antibacterials - Roche

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator Anadys Pharmaceuticals
  • Class Small molecules; Triazines
  • Mechanism of Action Cell wall inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Nosocomial infections

Most Recent Events

  • 04 Apr 2006 This programme is still in active development
  • 25 Jun 2004 This programme is still in active development - BIO 2004 Annual International Convention (BIO-2004)
  • 13 Jun 2002 Preclinical trials in Nosocomial infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top